Lucija Peterlin Masic
Overview
Explore the profile of Lucija Peterlin Masic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
968
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zorman M, Kokot M, Zdovc I, Senerovic L, Mandic M, Zidar N, et al.
Antibiotics (Basel)
. 2024 Nov;
13(11).
PMID: 39596774
Background: The novel bacterial topoisomerase inhibitors (NBTIs) developed in our laboratory show potent on-target enzyme inhibition but suffer from low activity against Gram-negative bacteria. Methods: With the aim of improving...
2.
Cotman A, Fulgheri F, Piga M, Persolja P, Tiz D, Skok Z, et al.
RSC Adv
. 2024 Sep;
14(39):28423-28454.
PMID: 39247510
This study presents the discovery of a new series of -phenylpyrrolamide inhibitors of bacterial DNA gyrase with improved antibacterial activity. The most potent inhibitors had low nanomolar IC values against...
3.
Zidar N, Onali A, Persolja P, Tiz D, Dernovsek J, Skok Z, et al.
Eur J Med Chem
. 2024 Sep;
278:116823.
PMID: 39236496
In this work, we describe an improved series of N-phenylpyrrolamide inhibitors that exhibit potent activity against DNA gyrase and are highly effective against high-priority gram-positive bacteria. The most potent compounds...
4.
Sterle M, Habjan E, Piga M, Persolja P, Durcik M, Dernovsek J, et al.
Eur J Med Chem
. 2024 Jul;
276:116693.
PMID: 39053193
New 2-pyrrolamidobenzothiazole-based inhibitors of mycobacterial DNA gyrase were discovered. Among these, compounds 49 and 51, show excellent antibacterial activity against Mycobacterium tuberculosis and Mycobacterium abscessus with a notable preference for...
5.
Zidar N, Cotman A, Sinnige W, Benek O, Barancokova M, Zega A, et al.
Bioorg Med Chem
. 2024 Jun;
109:117798.
PMID: 38906068
N-(Benzothiazole-2-yl)pyrrolamide DNA gyrase inhibitors with benzyl or phenethyl substituents attached to position 3 of the benzothiazole ring or to the carboxamide nitrogen atom were prepared and studied for their inhibition...
6.
Dobricic V, Marodi M, Markovic B, Tomasic T, Durcik M, Zidar N, et al.
J Chromatogr B Analyt Technol Biomed Life Sci
. 2024 May;
1240:124158.
PMID: 38776787
DNA gyrase and topoisomerase IV play significant role in maintaining the correct structure of DNA during replication and they have been identified as validated targets in antibacterial drug discovery. Inadequate...
7.
Durcik M, Cruz C, Scorciapino M, Ilas J, Tammela P, Ceccarelli M, et al.
RSC Adv
. 2024 Jan;
14(5):2905-2917.
PMID: 38239435
Benzothiazole-based bacterial DNA gyrase and topoisomerase IV inhibitors are promising new antibacterial agents with potent activity against Gram-positive and Gram-negative bacterial strains. The aim of this study was to improve...
8.
Sterle M, Durcik M, Stevenson C, Henderson S, Szili P, Czikkely M, et al.
ACS Omega
. 2023 Jul;
8(27):24387-24395.
PMID: 37457471
We present a new series of 2-aminobenzothiazole-based DNA gyrase B inhibitors with promising activity against ESKAPE bacterial pathogens. Based on the binding information extracted from the cocrystal structure of DNA...
9.
Gubic S, Montalbano A, Sala C, Becchetti A, Hendrickx L, Van Theemsche K, et al.
Eur J Med Chem
. 2023 Jul;
259:115561.
PMID: 37454520
Voltage-gated potassium channel K1.3 inhibitors have been shown to be effective in preventing T-cell proliferation and activation by affecting intracellular Ca homeostasis. Here, we present the structure-activity relationship, K1.3 inhibition,...
10.
Ruatta S, Prada Gori D, Flo Diaz M, Lorenzelli F, Perelmuter K, Alberca L, et al.
Front Pharmacol
. 2023 Jul;
14:1193282.
PMID: 37426813
The identification of chemical compounds that interfere with SARS-CoV-2 replication continues to be a priority in several academic and pharmaceutical laboratories. Computational tools and approaches have the power to integrate,...